Literature DB >> 11825733

Surgical management of acute aortic root endocarditis with viable homograft: 13-year experience.

A C Yankah1, H Klose, R Petzina, M Musci, H Siniawski, R Hetzer.   

Abstract

OBJECTIVE: Cryopreserved homograft valves have been used for acute infective aortic root endocarditis with great success but it is compounded by its availability in all sizes. The long-term clinical results of geometric mismatched homografts are not well defined and addressed.
METHODS: Over a 15-year period (April 1986-June 2001), 816 patients presented with active infective endocarditis. One hundred and eighty-two of the patients aged between 9 and 78 years (mean: 51.0 +/- 1.13 years) consisting of 142 males and 40 females received homograft aortic valves. One hundred and ten patients were in NYHA functional class III and 72 in class IV and in cardiogenic shock. Of the patients, 2.7% suffered from septic embolism. One hundred and twenty-four (68.1%) patients presented with periannular abscesses and 58 (31.9%) with no abscess while 107 native valve (NVE) and 75 prosthetic valve (PVE) endocarditis were diagnosed preoperatively by transesophageal echocardiography (TEE) and confirmed intraoperatively. Freehand subcoronary implantation (FSCI) was used in 106 patients and root replacement in 76 patients.
RESULTS: The operative death was 8.5% and for patients in NYHA functional class IV and in cardiogenic shock was 14.5%. Late mortality rate was 7.9%. Patient survival after discharge from hospital at 1 year was 97% and at 10 years was 91%, respectively. Thirty-one (22.1%) patients underwent reoperation after 1.7 years (mean) with two deaths (6.4%). Early (< or = 60 days) and late reinfection rate was 2.7 and 3.6%, respectively. Freedom from reoperation for matched and undersized homografts at 10-13 years was 85 and 55%, respectively. The univariate model identified undersized homograft (P=0.002), FSCI (P=0.09) and reinfection (P=0.0001) as independent risk factors for developing early and late valve dysfunction resulting in reoperation and homograft explant.
CONCLUSION: Early aggressive valve replacement with homograft for active infective aortic root endocarditis with periannular abscesses is more successful than delayed last resort surgery. Homografts exhibit excellent clinical performance and durability with a low rate of reinfection, if properly inserted. Undersized homograft is an incremental risk factor for early and late reoperation.

Entities:  

Mesh:

Year:  2002        PMID: 11825733     DOI: 10.1016/s1010-7940(01)01084-3

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  17 in total

Review 1.  The use of allogenic and autologous tissue to treat aortic valve endocarditis.

Authors:  Francesco Nappi; Sanjeet Singh Avtaar Singh; Mario Lusini; Antonio Nenna; Ivancarmine Gambardella; Massimo Chello
Journal:  Ann Transl Med       Date:  2019-09

2.  Complications of native and prosthetic valve infective endocarditis: update in 2006.

Authors:  Ignasi Anguera; Ana del Río; Asunción Moreno; Carlos Paré; Carlos A Mestres; José M Miró
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

3.  Bentall procedure using cryopreserved valved aortic homografts: mid- to long-term results.

Authors:  Jan T Christenson; Jorge Sierra; Pedro T Trindade; Didier Dominique; Afksendiyos Kalangos
Journal:  Tex Heart Inst J       Date:  2004

4.  Surgical treatment of aortic abscess and fistula.

Authors:  Nilgun Bozbuga; Vedat Erentug; Hasan Basri Erdogan; Kaan Kirali; Hasan Ardal; Serpil Tas; Esat Akinci; Cevat Yakut
Journal:  Tex Heart Inst J       Date:  2004

5.  Pseudoaneurysm developed after aortic root homograft implantation.

Authors:  Hiroo Takayama; Toshiya Otsuka; Hiroshi Kubota; Ko Shibata; Tadashi Kitamura; Shinichi Takamoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-03

6.  Infective Endocarditis in Intravenous Drug Abusers.

Authors:  José M. Miró; Asuncion Moreno; Carlos A. Mestres
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725

7.  Comparison of mid-term haemodynamic performance between the BioValsalva and the BioIntegral valved conduits after aortic root replacement.

Authors:  Daniel Wendt; Ayman Raweh; Stephan Knipp; Mohammed El Gabry; Mareike Eißmann; Daniel Sebastian Dohle; Konstantinos Tsagakis; Matthias Thielmann; Heinz Jakob; Jaroslav Benedik
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-04-04

8.  A case of staphylococcal tricuspid valve endocarditis with para-aortic abscess in a patient with bicuspid aortic valve.

Authors:  Woo Shin Kim; Seok Hyung Kang; Shin A Lee; Min Sun Ryu; Seong-Hoon Park
Journal:  Korean Circ J       Date:  2011-08-31       Impact factor: 3.243

9.  Systematic review and meta-analysis of surgical outcomes comparing mechanical valve replacement and bioprosthetic valve replacement in infective endocarditis.

Authors:  Campbell D Flynn; Neil P Curran; Stephanie Chan; Isabel Zegri-Reiriz; Manel Tauron; David H Tian; Gosta B Pettersson; Joseph S Coselli; Martin Misfeld; Manuel J Antunes; Carlos A Mestres; Eduard Quintana
Journal:  Ann Cardiothorac Surg       Date:  2019-11

10.  Twenty-Year Experience in the Diagnosis and Treatment of Infective Endocarditis.

Authors:  Elżbieta Abramczuk; Janina Stępińska; Tomasz Hryniewiecki
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.